Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX

Crinetics Pharmaceuticals Stock Analysis & Ratings

Crinetics Pharmaceuticals Stock Analysis Overview

Smart Score
7
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Crinetics Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

CRNX

CRNX Stock Stats

Previous Close$19
Open$19.21
Bid0 x 0
Ask29.46 x 40
Today’s Range$18.66 - $20.27
52-Week Range$13.83 - $28.95
Volume247.08K
Average Volume285.25K
Market Cap$899.65M
Beta1.34
P/E Ratio-6.8
EPS-2.78
Earnings DateMar 15, 2022

Company Description

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Sector
Healthcare
Industry
Biotechnology
CEO
R. Scott Struthers
Employees
93
Website
www.crinetics.com
ISIN
US22663K1079
Address
10222 Barnes Canyon Road, San Diego, CA, 92121, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

CRNX FAQ

What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $13.83 and its highest was $28.95 in the past 12 months.
    What is Crinetics Pharmaceuticals’s market cap?
    Crinetics Pharmaceuticals’s market cap is $899.65M.
      What is Crinetics Pharmaceuticals’s price target?
      The average price target for Crinetics Pharmaceuticals is $43.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $68.00 ,the lowest forecast is $35.00. The average price target represents 130.20% Increase from the current price of $18.94.
        What do analysts say about Crinetics Pharmaceuticals?
        Crinetics Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is Crinetics Pharmaceuticals’s upcoming earnings report date?
          Crinetics Pharmaceuticals’s upcoming earnings report date is Mar 15, 2022 which is in 47 days.
            How were Crinetics Pharmaceuticals’s earnings last quarter?
            Crinetics Pharmaceuticals released its earnings results on Nov 05, 2021. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.716 by -$0.014.
              Is Crinetics Pharmaceuticals overvalued?
              According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
                Does Crinetics Pharmaceuticals pay dividends?
                Crinetics Pharmaceuticals does not currently pay dividends.
                What is Crinetics Pharmaceuticals’s EPS estimate?
                Crinetics Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Crinetics Pharmaceuticals have?
                Crinetics Pharmaceuticals has 47,500,000 shares outstanding.
                  What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
                  Crinetics Pharmaceuticals reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.716. Following the earnings report the stock price went up 0.688%.
                    Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
                    Among the largest hedge funds holding Crinetics Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Crinetics Pharmaceuticals’s shares valued at 83M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis